AstraZeneca Bristol Myers megadeal explorations
AstraZeneca Bristol Myers megadeal explorations indicate that AZ has explored a potential Bristol Myers Squibb acquisition valued around $400 billion, though
Bristol Myers Squibb, Hengrui in collaboration licensing
The collaboration licensing deal valuation for Bristol Myers Squibb and Jiangsu Hengrui Pharmaceuticals could reach up to $15.2 billion, spanning oncology,